10/05/2024  17:51:25 Diferencia +38.0000 Volumen Bid18:30:00 Ask18:30:00 Capitalización de mecado Dividendo A. P/E Ratio
12,370.0000GBX +0.31% 1.41 millones
Volumen de negocios(GBP): 124.29 millones
11,500.0000Volumen de oferta: 4,000 12,470.0000Tamaño/ Volumen/ Formato de Ask: 500 191.74 mil millonesGBP - -

Descripción de negocio

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 

Consejo de gestión & Consejo de supervisión

CEO
Pascal Soriot
Consejo de gestión
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr
Consejo de supervisión
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg
 

Datos de la empresa

Nombre: AstraZeneca plc
Dirección: 1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom
Teléfono: 0800 783 0033
Fax: +44-20-7604-8151
E-mail: Medical.InformationU...eca.com Medical.InformationUK@astrazeneca.com
Internet: www.astrazeneca.com
Industria: Healthcare
Sector: Pharmaceutical Industry
Subsector: Pharmaceuticals
Fin del año financiero: 31/12
Acciones de libre circulación: -
Fecha de OPI: 06/04/1999

Relación con inversores

Nombre: Andy Barnett
IR teléfono: +44 (0)20 3749 5000
IR-fax: -
IR e-mail: CorporateAccess@astrazeneca

Calendario de la empresa

CW 30 | 25/07/2024 Interim Report 2nd Quarter/6 Months
CW 32 | 08/08/2024 Ex-Dividend
CW 32 | 09/08/2024 Record Date
CW 37 | 09/09/2024 Dividend Payment
CW 46 | 12/11/2024 Interim Report 3rd Quarter/9 Months
 

Accionistas mayoritarios

Otros
 
77.64%
BlackRock, Inc.
 
6.51%
Wellington Management Company LLP
 
4.20%
Wellington Management Group LLP
 
4.20%
The Capital Group Companies, Inc
 
4.12%
Investor AB
 
3.33%